Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Buys 50,000 Shares

Benitec Biopharma Limited (NASDAQ:BNTC) Director Suvretta Capital Management, L bought 50,000 shares of the business’s stock in a transaction dated Tuesday, December 23rd. The stock was acquired at an average cost of $12.85 per share, for a total transaction of $642,500.00. Following the purchase, the director owned 9,620,075 shares in the company, valued at approximately $123,617,963.75. This trade represents a 0.52% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Suvretta Capital Management, L also recently made the following trade(s):

• On Monday, December 29th, Suvretta Capital Management, L purchased 77,387 shares of Benitec Biopharma stock. The shares were acquired at an average cost of $13.44 per share, with a total value of $1,040,081.28.
• On Friday, December 26th, Suvretta Capital Management, L purchased 16,836 shares of Benitec Biopharma stock. The stock was bought at an average price of $13.10 per share, with a total value of $220,551.60.
• On Monday, December 22nd, Suvretta Capital Management, L acquired 19,542 shares of Benitec Biopharma stock. The shares were bought at an average price of $12.08 per share, for a total transaction of $236,067.36.
• On Friday, December 19th, Suvretta Capital Management, L bought 16,384 shares of Benitec Biopharma stock. The stock was bought at an average cost of $11.48 per share, with a total value of $188,088.32.
• On Thursday, December 18th, Suvretta Capital Management, L bought 10,215 shares of Benitec Biopharma stock. The shares were bought at an average price of $11.24 per share, for a total transaction of $114,816.60.
• On Friday, November 7th, Suvretta Capital Management, L purchased 1,481,481 shares of Benitec Biopharma stock. The shares were bought at an average cost of $13.50 per share, for a total transaction of $19,999,993.50.

Benitec Biopharma Trading Up 3.0%

NASDAQ:BNTC traded up $0.39 during trading hours on Monday, hitting $13.49. The stock had a trading volume of 200,584 shares, compared to its average volume of 243,420. The business has a 50 day simple moving average of $13.55 and a two-hundred day simple moving average of $13.36. The company has a market cap of $456.77 million, a PE ratio of -11.15 and a beta of 0.20. Benitec Biopharma Limited has a 1-year low of $9.70 and a 1-year high of $17.15.

Benitec Biopharma (NASDAQ:BNTC) last released its quarterly earnings results on Friday, November 14th. The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.13. Research analysts expect that Benitec Biopharma Limited will post -1.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on BNTC. Citigroup restated an “outperform” rating on shares of Benitec Biopharma in a research note on Tuesday, November 4th. JMP Securities set a $22.00 target price on shares of Benitec Biopharma in a research note on Tuesday, November 4th. Oppenheimer reaffirmed an “outperform” rating and set a $29.00 price target (down previously from $35.00) on shares of Benitec Biopharma in a research report on Tuesday, September 16th. Zacks Research raised Benitec Biopharma from a “strong sell” rating to a “hold” rating in a report on Friday, November 14th. Finally, HC Wainwright set a $32.00 price objective on Benitec Biopharma and gave the company a “buy” rating in a research note on Monday, November 24th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.25.

Hedge Funds Weigh In On Benitec Biopharma

Several institutional investors have recently made changes to their positions in BNTC. BNP Paribas Financial Markets raised its position in shares of Benitec Biopharma by 44.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 904 shares during the period. Police & Firemen s Retirement System of New Jersey acquired a new position in Benitec Biopharma during the 2nd quarter valued at approximately $38,000. Russell Investments Group Ltd. bought a new position in Benitec Biopharma during the 3rd quarter worth $79,000. Bank of America Corp DE grew its stake in Benitec Biopharma by 2,255.8% during the 2nd quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company’s stock worth $80,000 after buying an additional 6,587 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in Benitec Biopharma in the second quarter worth $80,000. 52.19% of the stock is owned by institutional investors.

Benitec Biopharma Company Profile

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.